We assign Siegfried a Medium Morningstar Uncertainty Rating. Its business is relatively stable, with high switching costs and good visibility due to long-term customer contracts. However, small ...

Direct-to-consumer telehealth company advertisement that aired during the Super Bowl failed to mention side effects of the drugs.

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...

A pair of Chinese manufacturers with active pharmaceutical ingredients that were previously shipped to the U.S. | The FDA ...

A federal judge will soon decide whether to dismiss a lawsuit against UnitedHealth Group alleging that the company and its ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

A reporter uncovers evidence that research fraud on a massive scale has hyped the potential benefit of expensive drugs aimed ...

Hims and Hers has been slammed for its Super Bowl commercial that admonished Americans for being obese and shamed the healthcare industry - then promoted its own weight loss drugs.  The 60-second ...

The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded drugs — not be false or misleading,” contended Pharmaceutical Research and ...

Shares of Hims & Hers Health Inc. jumped nearly 4% in early premarket trading Monday, on track for fresh record highs, after the company aired a provocative Super Bowl ad that targeted Big Pharma and ...

Vertex Pharmaceuticals ... the billions of dollars. The company is in the early days of a new and exciting growth story. That's why, following this recent FDA approval, Vertex stock makes a ...